Hikma Pharmaceuticals PLC CEO Said Darwazah discusses Full Year 2025 performance and results

In this video, Hikma Pharmaceuticals CEO, Said Darwazah provides an overview of Hikma’s Full Year 2025 performance. He discusses key highlights, strategic progress, achievements, priorities, and the outlook for the year ahead. This video is part of Hikma’s full year results announcement for investors, analysts, and stakeholders.

Hello everyone. Today we announced our financial results, and I am pleased with the performance Hikma delivered in 2025, growing the business and delivering results aligned with market expectations.

We launched 84 products during the year, continued to sign new partnerships and achieved important business milestones.

And I am very proud to say that we became the largest pharmaceutical company in MENA by sales, for the first time in the history of the company.

We have three excellent businesses, all with unique strengths.

To be clear, we also had our challenges. We have begun implementing changes in the business to address these, including to the leadership, and we have been taking a close look at where we need to strengthen the Group, and in particular, our Injectables business.

Branded, our MENA based business, is truly best-in-class.

We’re a leader in the region, where we operate among the large multinationals.

We have a strong team, with local market expertise, a broad portfolio of world-class products, a wealth of manufacturing capabilities and excellent customer relationships.

Branded is a consistently strong performer and a true backbone of Hikma’s strengths.

Hikma Rx has become an increasingly important business for us in recent years as we have pursued growth in higher value areas, such as our more complex medicines and through offering CMO services. I’m excited by the rapid progress we are making in Hikma Rx. We are one of the leading US domestic producers of generic medicines and we are proud of the positive impact this business is having on the US healthcare landscape.

For Injectables, while our margins are very strong for the industry, we must continue to invest to achieve the full potential of this business. We are increasing our investment in R&D, in people, and in capex to position ourselves for higher levels of consistent profitable growth.

We are entering 2026 energised and focused on delivering on our strategy. While we have had to adjust our expectations, I am confident that guidance we are providing for this year is realistic and reflects the investments we need to make. I’m excited to show that we can deliver on this over the year ahead.

Hikma has a rich history and a track record of growth.

The work we do at Hikma is important, improving access to quality healthcare for hundreds of millions of people, and it is our talented people who make this happen. I would like to thank my Hikma colleagues for their hard work throughout 2025.

Thank you.